Investor

Overview Share information Financial calendar Reports & presentations Governance

Investor relations

We are committed to providing all shareholders and potential investors with consistent, transparent, and relevant financial information. This section offers key insights into Lifecare.

NOK –

Last updated 1970-01-01 00:00:00

Change +0.00

Volume 0,000

High 0.00 NOK

Low 0.00 NOK

Exercise period for warrants series 1

The exercise period for warrants series 1 issued in connection with the rights issue in January 2026 commenced 2 March 2026 and expires 13 March 2026. Each warrant gives the holder a right to subscribe for one new share at an exercise price of NOK 0.3342 per share.

Warrants not sold within 6 March 2026 or exercised within 13 March 2026 will lapse with no compensation.

Company presentation

Lifecare is a Norwegian med-tech company developing sensors to measure and monitor biomarkers. We focus on diabetes, aiming to bring the next generation of continuous glucose monitoring (GCM) systems to improve diabetes management for humans and pets.

Investment case

Diabetes is a trillion-dollar global healthcare challenge. CGMs is the fastest growing diabetes tech segment, representing a USD 30 billion market opportunity. Within CGMs, implantable solutions represent a USD 5 billion potential market. Click here for more about how Lifecare intends to capture a share of the implantable CGM market and create value for our stakeholders.

Stock exchange notices

IR contacts

Joacim Holter

Chief Executive Officer

+47 400 59 040 joacim.holter@lifecare.no

Renete Kaarvik

Chief Financial Officer

+47 94838242 renete.kaarvik@lifecare.no